C12N 2770/18034
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/18034 (Use of virus or viral component as vaccine) appears on 20 US grants and 35 published applications in this corpus.
Search patents in C12N- Granted patents
- 20
- Published applications
- 35
- Assignees
- 25
- Inventors
- 97
- Latest grant
- 11 Nov 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 1 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 1 | 1 |
| 2019 | 0 | 1 |
| 2020 | 0 | 0 |
| 2021 | 0 | 5 |
| 2022 | 3 | 5 |
| 2023 | 4 | 7 |
| 2024 | 6 | 8 |
| 2025 | 5 | 6 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Cancer immunotherapy using virus particles and immune checkpoint therapy11 Nov 2025US 12,465,624 B2Case Western Reserve University
- Conserved region T cell vaccines for coronavirus and methods of use22 Jul 2025US 12,364,750 B1Beth Israel Deaconess Medical Center, Inc.
- Recombinant multivalent influenza viruses6 May 2025US 12,290,562 B2Wisconsin Alumni Research Foundation (WARF)
- Compositions and methods of mRNA vaccines against novel coronavirus infection22 Apr 2025US 12,280,105 B2RNAimmune, Inc.
- Sustained release cowpea mosaic virus or virus-like particle therapeutic constructs for the treatment of cancer7 Jan 2025US 12,186,279 B2Case Western Reserve University
- Cancer immunotherapy using virus particles and immune checkpoint therapy25 Jun 2026US 2026/0174813 A1Case Western Reserve University
- Cancer therapy23 Oct 2025US 2025/0325608 A1The Regents of the University of California
- Coronavirus vaccine31 Jul 2025US 2025/0242059 A1BioNTech SE
- Novel plant virus and bacteriophage vaccines26 Jun 2025US 2025/0205331 A1The Regents of the University of California
- Melt processed viral nanoparticle constructs19 Jun 2025US 2025/0195449 A1Case Western Reserve University
Most cited
By later US patents
- Mouse-adapted SARS-CoV-2 viruses and methods of use thereof12US 11,225,508 B1The University of North Carolina at Chapel Hill · 2022
- Coronavirus vaccine9US 11,547,673 B1BioNTech SE · 2023
- RNA constructs and uses thereof4US 11,779,659 B2BioNTech SE · 2023
- Recombinant multivalent influenza viruses2US 12,290,562 B2Wisconsin Alumni Research Foundation (WARF) · 2025
- Vaccines for porcine epidemic diarrhea virus infections1US 10,143,739 B2Kansas State University Research Foundation · 2018